Advertisement
Canada markets open in 2 hours 52 minutes

  • S&P/TSX

    22,011.72
    +139.76 (+0.64%)
     

  • S&P 500

    5,070.55
    +59.95 (+1.20%)
     

  • DOW

    38,503.69
    +263.71 (+0.69%)
     

  • CAD/USD

    0.7309
    -0.0011 (-0.15%)
     

  • CRUDE OIL

    83.04
    -0.32 (-0.38%)
     

  • Bitcoin CAD

    90,855.70
    +187.30 (+0.21%)
     

  • CMC Crypto 200

    1,433.21
    +9.11 (+0.64%)
     

  • GOLD FUTURES

    2,330.80
    -11.30 (-0.48%)
     

  • RUSSELL 2000

    2,002.64
    +35.17 (+1.79%)
     

  • 10-Yr Bond

    4.5980
    -0.0250 (-0.54%)
     

  • NASDAQ futures

    17,708.00
    +101.25 (+0.58%)
     

  • VOLATILITY

    15.83
    +0.14 (+0.89%)
     

  • FTSE

    8,089.87
    +45.06 (+0.56%)
     

  • NIKKEI 225

    38,460.08
    +907.92 (+2.42%)
     

  • CAD/EUR

    0.6836
    0.0000 (0.00%)
     

ZY ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of October 4, 2021 in the Class Action Filed on Behalf of Zymergen Inc. Limited Shareholders

Newsfile Corp.
·2 min read

New York, New York--(Newsfile Corp. - September 23, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Zymergen Inc. (NASDAQ: ZY) alleging that the Company violated federal securities laws.

This lawsuit is on behalf of investors who purchased ZY common stock pursuant and/or traceable to the documents issued in connection with the Company's April 2021 initial public offering.

Lead Plaintiff Deadline: October 4, 2021
No obligation or cost to you.

Learn more about your recoverable losses in ZY:
https://www.kleinstocklaw.com/pslra-1/zymergen-inc-loss-submission-form?id=19787&from=5

Zymergen Inc. NEWS - ZY NEWS

CLASS ACTION CASE DETAILS: The filed complaint alleges that Zymergen Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) during the qualification process for the Company's optical film product, Hyaline, key customers had encountered technical issues, including product shrinkage and incompatibility with customers' processes; (2) though the qualification process was critical to achieving market acceptance for Hyaline and generating revenue, Zymergen lacked visibility into the qualification process; (3) as a result, the Company overestimated demand for its products; (4) as a result of the foregoing, the Company's product delivery timeline was reasonably likely to be delayed, which in turn would delay revenue generation; and (5) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.

ADVERTISEMENT

WHAT THIS MEANS TO YOU AS A SHAREHOLDER: If you have suffered a loss in Zymergen you have until October 4, 2021 to petition the court for lead plaintiff status. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

NO COST TO YOU: If you purchased Zymergen securities during the relevant period, you may be entitled to compensation without payment of any out-of-pocket fees.

HOW TO PROTECT YOUR FINANCIAL INTERESTS: For additional information about the ZY lawsuit, please contact J. Klein, Esq. by telephone at 212-616-4899 or click this link.

ABOUT KLEIN LAW FIRM
J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. The Klein Law Firm is a boutique litigation firm with experience in a wide range of areas including securities law, corporate finance and commercial litigation. Since 2011, our experienced attorneys have achieved superior results for our clients with a personalized focus. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
jk@kleinstocklaw.com
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/97401